Treatment failure in acute myeloid leukemia (AML) is frequently due to the persistence of a cell population resistant to chemotherapy through different mechanisms, in which a drug efflux via ATP-binding cassette (ABC) proteins, specifically P-glycoprotein, is one of the best recognized. However, the large number of failed clinical trials employing inhibitors for these transporters has demonstrated the necessity to adopt different strategies. We hypothesized that microtubule targeting compounds presenting high affinity or covalent binding could overcome the effect of the ABC-transporters. We therefore evaluated the activity of the high-affinity paclitaxel analogue chitax-40 (CTX-40) as well as the covalent binder zampanolide (ZMP) and novel ZMP-derivatives in AML cells. All molecules were active in chemosensitive and chemoresistant cell lines overexpressing P-glycoprotein, being ZMP and CTX-40 the most effective. Moreover, ZMP or CTX-40 in combination with daunorubicin showed synergistic killing without increased in vitro hematopoietic toxicity. In addition, we demonstrated that ZMP and CTX-40 are active in the progenitor and differentiated AML populations from a primary sample. In sum, our data indicates that high 2 affinity and covalent-binding anti-microtubule agents are active in otherwise chemotherapy resistant AML cells.
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Introduction
Acute myeloid leukemia (AML) is a clonal disorder characterized by the inhibition of differentiation with the resulting accumulation of immature cells in the bone marrow and/or peripheral blood (Ferrara and Schiffer 2013) . The current treatment of most common types of AML has hardly changed over the past three decades, and is composed of induction chemotherapy (usually a combination of cytarabine and an anthracycline), followed by either consolidation chemotherapy or allogeneic stem cell transplantation (Roboz 2012) .
Although this treatment leads to a complete remission in the majority of patients, only 40 % of younger than 60 years and 10 to 20 % of older patients remain in remission (Peloquin, Chen et al. 2013 ).
Treatment failure it has been frequently associated to the persistence of cell population that is inherently resistant to chemotherapeutic agents (Tallman, Gilliland et al. 2005 , Ishikawa, Yoshida et al. 2007 ). One of these resistance mechanisms is due to an increased cellular efflux of drugs via transmembrane proteins of the ATP-binding cassette (ABC) family, including P-glycoprotein (P-gp), multidrug resistance-associated protein 1, and breast cancer resistance protein (Wulf, Wang et al. 2001 , van den Heuvel-Eibrink, van der Holt et al. 2007 ). The main approach to overcome the efflux of chemotherapy agents in AML has involved the co-administration of competitive inhibitors of these pumps. However, the large number of failed clinical trials involving ABC family inhibitors has demonstrated the necessity to adopt different strategies (Libby and Hromas 2010) .
Development of tubulin-binding agents with high binding affinity has been proposed as an alternative strategy to overcome the transport efflux (Buey, Calvo et al. 2007 , Yang, Barasoain et al. 2007 , Matesanz, Barasoain et al. 2008 . In a proof-of-principle experiment, we previously reported that a taxane-derivative with 500-fold higher affinity than paclitaxel, CTX-40, can effective overcome efflux pumps, including P-gp (Matesanz, Barasoain et al. 2008 , Cai, Lu et al. 2013 . Likewise, the tubulin covalent-binding drug zampanolide (ZMP) showed activity in one breast cancer cell line overexpressing drug pumps (Field, Pera et al. 2012) , suggesting that this could also be a valid strategy for killing chemoresistant cells.
Herein, we determined the anti-leukemic effects of CTX-40, ZMP and a series of novel synthetic structurally simplified ZMP-derivatives ( Figure 1 ) in chemotherapy-resistant AML cell lines and in an AML primary sample. We also characterized the effect of their combination with the anthaycline daunorubicin, as well as their toxicity to human hematopoietic progenitors and stem cells (HPSCs). 
Materials and methods
Reagents
Cell lines and primary specimens
Human umbilical cord blood (CB) from healthy full-term pregnancies was provided by the New York Blood Center. Human CD34 + cells were isolated from Ficoll-separated mononuclear CB cells using the MiniMACS CD34 isolation kit (Milteny Biotech) as previously described (Chung, Morrone et al. 2005 ). 
In vitro toxicity studies
Growth inhibition 50 (GI 50 ) values for the tested molecules were determined by a fluorescence assay using 7-Hydroxy-3H-phenoxazin-3-one 10-oxide (alamar blue, Invitrogen) according to the manufacturer's protocol after 72 h of drug incubation period.
Cell cycle assays
Cell cycle fractions were determined by propidium iodide nuclear staining. Briefly, cells
were harvested, washed in PBS, fixed with 70 % ethanol, and incubated with propidium iodide/RNase buffer (BD Bioscience) for 24 h at 4 ºC. Data were collected on a BD LSR Fortessa fluorescence-activated cell analyzer using BD FACS Diva software and analyzed using FlowJo version 10.0.6 (Tree Star Inc.).
Immunoblot analyses
Protein concentrations were determined using the BCA kit (Pierce Biotechnology)
according to the manufacturer's instructions. Protein lysates (15 -30 µg) were electrophoretically resolved by SDS/PAGE, transferred to nitrocellulose membrane, and probed with the indicated primary antibodies: Anti-Mdr-1 (1:500, sc-55510; Santa Cruz).
Equal loading of the protein samples was confirmed by parallel western blots for β-actin
(1:50,000, ab822750; Abcam). We used ECL-Enhanced Chemiluminescence Detection System (GE Healthcare Biosciences, Pittsburgh, PA) according to the manufacturer's instructions and the blots were visualized by autoradiography. Quantitative densitometry analysis of western blot bands was performed employing Image J version 10.2 software (NIH). The normalized relative densities were calculated relative to the expression of β-actin.
Real-time qPCR
Total RNA was extracted from 5 x 10 6 cells with the use of the RNeasy Mini Plus kit (Qiagen) and eluted in RNAse-free water. cDNA was synthesized using high capacity RNA-to-cDNA kit (Applied Biosystems). Primer sequence for MDR-1 was published in (Lobert, Hiser et al. 2010) . SYBR Green FastMix was from Quanta BioSciences. The thermal cycling parameters are as follows: (…).
Caspase assays
Caspase-3 and -7 activity was determined employing the Apo-ONE caspase 3/7 assay (Promega) following the manufacturer's instructions and measuring the fluoresence emission in a Synergy4 microplate reader (BioTek). Caspase activity was normalized by the cell number determined by alamar blue. Caspase-9 inhibitor I was from Calbiochem and caspase-8 inhibitor was from G-Biosciences. (Breems, Blokland et al. 1994 ).
Colony-forming unit (CAFC) and cobblestone area-forming cell (CAFC) assays for hematopoietic stem and progenitor (HSPC) cells
CAFCs for leukemic stem cells
MS-5 mouse bone marrow-derived stromal cells were plated in 96-well format (20,000 cells per well in α-MEM) and kept at 37 ºC / 5 % CO 2 . One day later, CD34 + preincubated primary-leukemic cells were added in 100 µL of fresh co-culturing medium (α-Eagle's minimum essential medium, 12.5 % horse serum, 12.5 % FBS, 200 mM glutamine, 1 % penicillin and streptomycin, 1 mM monothioglycerol and 1 µM hydrocortisone) at a density determined in order to generate 10 cobblestones per well after 2 weeks (Moore, Dorn et al. 2007 ) in neutral control wells. The co-cultures were then maintained and assessed for cobblestone at week 2.
Drug combination analysis
Drug interaction evaluation was assessed employing the combination index (CI) equation of Chou and Talalay (Chou and Talalay 1984) and Berenbaum (Berenbaum 1985 correspond to those used in combination, and the doses Dx 1 and Dx 2 correspond to the amounts of each drug given alone that would produce the same response as obtained with the combination. In order to calculate the concentration of drug needed for a given response on its own, the following equation was used: Dose (x) = GI 50 x (max -response / response -min) 1/hillslope . GI 50 and values for minimum (min), maximum (max) and hillslope were obtained using GraphPad Prism version 6.0b software.
Results
High affinity and covalent tubulin-binding agents inhibited proliferation of drugresistant leukemic cells
We determined the activity of high affinity and covalent binding microtubule stabilizing agents in in a panel of six human leukemia cell lines that included the P-gp overexpressing cell lines KG-1a (acute myeloid leukemia, AML) (Koeffler, Billing et al. 1980 , Wang, Wang et al. 2014 ) and CCRF-CEM/VBL (acute lymphoid leukemia, ALL) (Bacherikov, Chou et al. 2004 ) (Supplementary Figure 1) . We compared their effect against clinically used chemotherapy drugs for leukemia treatment, daunorubicin and cytarabine. We used paclitaxel as control for CTX-40 since this compound is a paclitaxel derivative with 500 fold higher binding affinity for tubulin. We exposed cells to these compounds for 72h and measured viability by a metabolic dye reduction assay (alamar blue). We found that all the compounds reduced leukemia cell proliferation (Table 1 and 2). Daunorubicin and paclitaxel increased their GI 50 in P-gp overexpressing cells by 10 and 60 fold, respectively (p < 0.05, Table 1 ), while cytarabine, maintained its effect (Table 1) . On the contrary, ZMP showed sub-nanomolar GI 50 values in all the P-gp-expressing cell lines, and CTX-40 increased its GI 50 value, although within the nanomolar range, only in CCRF-CEM/VBL cells (Table 1 ). All ten ZMP-derivatives reduced cell proliferation at the micromolar range and retained activity in PgP-expressing resistant cell lines (Table 2) . Taken together, these results demonstrate that compounds with high affinity or covalent binding are able to circumvent the effect of pump efflux.
ZMP and CTX-40 induced cell cycle arrest and apoptosis in AML cells
To further characterize the anti-leukemic effect of the compounds ZMP and CTX-40, we exposed the sensitive cell line MV4-11 and the resistant cell line KG-1a to three concentrations of drugs for 12 and 24h, and measured cell cycling by DNA deconvolution.
We found that ZMP and CTX-40 induced cell cycle arrest characterized by an increased of the fraction of cells in G 2 /M phase and a decreased of the cell fraction at G 0 /G 1 (Figure 2 ).
The cycle arrest in MV4-11 occurred at 12 hours (Figure 2a) , while in the P-gp overexpressing cell line, KG-1, the effect was more evident at 24 hours (Figure 2b) . To determine whether G 2 /M arrest was followed by cell death, we analyze the induction of apoptosis by determining the activation of caspase-3 and -7. We found that both compounds induced activation of caspase-3/-7 (Figure 3) . Moreover, in presence of the caspase-8 or -9 inhibitors this activity was notably reduced (Figure 3a and b) , suggesting that ZMP and CTX-40 induce apoptosis in MV4-11 and KG-1a cells through engaging intrinsic and extrinsic apoptotic pathways.
ZMP and CTX-40 synergized with daunorubicin in MV4-11 and KG-1a cells
To determine whether ZMP and CTX-40 synergizes with daunorubicine, we exposed chemoresistant (KG-1a) and chemosensitive (MV4-11) AML cells to the concurrent and sequential combination of these drugs and measure their anti-proliferative effect. The combinatorial effect was determined by the combination index (CI) Talalay 1984, Berenbaum 1985) , where CI values less than 1.0 indicates a synergistic effect between two drugs. We found that the combinations of daunorubicine with ZMP and CTX-40 in KG-1a and MV4-11 cell lines were synergistic (Table 3) . Remarkably, these results indicated a statistically significant effect for the combination even when ZMP and CTX-40
were administered at concentrations four-time lower than their GI 50 (Table 3 ). There were not differences on the synergistic effect when drugs were administered sequentially (i.e. daunorubicin for 24 h followed by ZMP or CTX-40) (Supplementary Table 1 (Fig. 4b right) .
ZMP and CTX-40 showed activity against AML-patient derived CD34 + leukemic cells.
To determine (Figure 5a and 5b).
Discussion
In the present study, we have demonstrated that microtubule-targeting agents ( values in the subnanomolar range, thus around 100 folds more potent than cytarabine. We obtained a resistance ratio (R/S), i.e. GI 50 (resistant)/GI 50 (sensitive), in AML cell lines of around 650 for paclitaxel and 13 for CTX-40, making CTX-40 50-times more active than paclitaxel. Collectively, our results indicated that CTX-40 is less affected by P-gp-mediated resistance at cellular level than its parental compound paclitaxel, and that the effect of ZMP and its novel derivatives are not decreased due the efflux transport.
All the novel ZMP derivatives tested showed antileukemia activity with GI50s from high nanomolar to low micromolar range. This variation in their potency is in agreement with the work published by Prota et al. (Prota, Bargsten et al. 2013 ) that demonstrated the requirement of the N-acyl-hemiaminal of ZMP to interact with the M-loop of β-tubulin to stabilize the microtubules. In our study, the most active ZMP derivatives were MJ-75 and epi-MJ-75 that preserved both the hydroxyl group in C20 responsible of the formation of a hydrogen bond with the M-loop.
Although ZMP and CTX-40 decreased the number of normal hemopoietic colonies, this effect was comparable to that induced by cytarabine. More remarkable was the effect of these drugs in killing leukemic cells from an AML patient. This patient presented an activating mutation of the FML-like tyrosine kinase 3 (Flt3), that are found in 30% of all AML cases (Kiyoi, Towatari et al. 1998) and are associated with an aggressive disease phenotype and poor outcomes (Patel, Gonen et al. 2012) . We showed here that ZMP and CTX-40 were able to kill the tumor bulk as well as the quiescent leukemic stem cell population.
In sum, we showed here that is feasible to overcome the effect of efflux pumps affecting chemotherapy drugs, by employing compounds with higher affinity or covalent binding to tubulin. Our study presents ZMP and CTX-40 as promising candidates for in vivo evaluation to validate their possible therapeutic use in AML.
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Supplementary Figure 1
Transcript abundance (fold change relative to MV4-11) of MDR-1 in the leukemia cell lines employed in the study, determined by RT-qPCR (A). PCR products were analyzed using 1 % agarose gel electrophoresis.
